Plain-English translation of NCT07465835 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is the first human study of , a new medication designed to treat certain blood cancers (T-cell and NK-cell malignancies) that have come back or stopped responding to other treatments. The trial has two phases: first, researchers will test different doses to find the safest level; then, they will enroll more patients to learn whether the medication actually helps. This study is for people whose cancer has been difficult to control with standard options.
Patients with these blood cancers often run out of effective treatment options when their disease comes back or becomes resistant to available drugs. This trial exists to see whether this new medication could offer hope to people in that difficult situation.
You likely qualify if…
You likely don't qualify if…
You would first have a screening visit lasting up to 4 weeks to confirm you qualify. Then you would receive the medication for up to 6 months (broken into 4-week cycles), with regular clinic visits to check how you're doing and watch for side effects. After treatment ends, you would have a follow-up visit 28 days later, and then doctors would track your survival for up to 2 years. If the medication is working well for you, your doctor may ask the trial sponsor if you can continue treatment for a few more months.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
United States